If you're a qualified researcher studying endocrine signalling, metabolic regulation, or growth-hormone-releasing pathways, CJC-1295 peptide is likely already on your radar. At PeptideValidation.com, we supply research-grade CJC-1295 as a 5 mg lyophilized powder intended exclusively for controlled laboratory studies. This article breaks down the compound's structure, its role in peptide-signalling research, quality verification requirements, and what the published science actually shows, so your lab starts from a solid, well-documented baseline.
What Is CJC-1295 Peptide?
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of 30 amino acids. It is designed to mimic the first 29 residues of endogenous GHRH while incorporating a Drug Affinity Complex (DAC) modification in some variants, which extends its half-life from minutes to several days by binding covalently to serum albumin.
CJC-1295 belongs to a class of research peptides called GHRH analogues. The native GHRH molecule has a very short circulating half-life of roughly 7 minutes, making it difficult to study sustained GH-axis effects in laboratory models. CJC-1295 was developed to address that limitation.
Two main variants exist in the research literature. The first is CJC-1295 without DAC (also called Mod GRF 1-29), which preserves a shorter, more pulsatile activity window. The second is the CJC-1295 DAC peptide, where the Drug Affinity Complex modification allows albumin binding and extends the half-life to approximately 6 to 8 days in preclinical models. Researchers choose between them based on the kinetic profile their study design requires.
At the molecular level, CJC-1295 binds the GHRH receptor (GHRHR) on somatotroph cells of the anterior pituitary. This binding stimulates adenylyl cyclase, raises intracellular cAMP, and triggers growth hormone secretion. Because the compound targets an upstream receptor rather than GH itself, it has become a useful tool in studies examining the broader somatotropic axis.
CJC-1295 is not a steroid. This distinction matters because researchers sometimes encounter the question "is CJC-1295 a steroid" when reviewing regulatory frameworks or institutional protocols. Steroids are lipid-based molecules derived from cholesterol. CJC-1295 is a peptide, meaning it is a short chain of amino acids with no steroid ring structure.
How CJC-1295 Works in Peptide-Signalling Research
CJC-1295 activates the GHRH receptor on pituitary somatotrophs, triggering a cAMP-mediated cascade that stimulates growth hormone release. In DAC-modified forms, albumin binding extends this signalling window from minutes to several days, allowing researchers to study sustained GH-axis responses in controlled models.
Understanding the signalling pathway is essential before designing any in vitro or in vivo study with CJC-1295. The compound's primary mechanism runs through the GHRHR, a G-protein-coupled receptor. Activation raises cAMP concentrations inside somatotroph cells, which in turn activates protein kinase A and promotes GH granule exocytosis.
Downstream, released GH stimulates hepatic production of insulin-like growth factor 1 (IGF-1). The GH/IGF-1 axis is central to a wide range of metabolic processes, including protein synthesis, lipolysis, and glucose regulation. Studies using CJC-1295 in animal models have examined how sustained GHRH-receptor activation affects these downstream markers over multi-day windows.
The DAC modification deserves specific attention. DAC chemistry uses a maleimide linker that reacts with the free thiol group on cysteine-34 of serum albumin. Once bound, the albumin-peptide complex circulates for days rather than minutes. A 2006 paper by Ionescu and colleagues published in the Journal of Clinical Endocrinology and Metabolism documented dose-dependent GH increases lasting up to 6 days in human subjects, which is useful context for designing comparable animal-model timelines.
Researchers studying metabolic or endocrine outcomes typically track at least three downstream markers: serum GH concentration, plasma IGF-1 levels, and, where relevant, markers of lean-tissue protein turnover. Establishing baseline values before compound introduction is standard practice and directly affects the reproducibility of results across batches.
CJC-1295 Peptide Dosage Considerations in Preclinical Studies
Published preclinical dosage ranges for CJC-1295 vary by variant and model species. Researchers should derive study-specific doses from peer-reviewed literature and institutional protocols rather than from anecdotal sources.
Dosage is one of the most searched aspects of CJC-1295 research, and for good reason. Getting the dose-response curve right is foundational to generating reproducible data. The literature distinguishes clearly between CJC-1295 with and without DAC because the two variants have very different pharmacokinetic profiles.
For CJC-1295 without DAC, preclinical rodent studies have used doses in the range of 1 to 10 micrograms per kilogram to characterise short-window GH pulses. The compound's rapid clearance means dosing intervals in these models are typically measured in hours. For CJC-1295 with DAC dosage protocols, animal studies exploring sustained GH elevation have used single-dose ranges from roughly 25 to 125 micrograms per kilogram, with follow-up sampling spanning multiple days to capture the albumin-bound fraction's extended activity.
These are research parameters derived from controlled studies, not clinical recommendations. Any CJC-1295 peptide dosage used in your lab must be grounded in your specific model organism, the endpoints you're measuring, and approval from your institutional review or IACUC committee.
One practical note: because CJC-1295 is supplied as a lyophilized powder (5 mg per vial in PeptideValidation.com's research-grade format), accurate reconstitution arithmetic is critical. A documentation error at the dilution step can shift a study's effective dose by an order of magnitude. Many labs maintain a written reconstitution log as part of their standard operating procedures.
CJC-1295 Side Effects and Safety Observations in Published Research
Preclinical and early clinical studies have documented several physiological responses associated with CJC-1295 exposure, including transient flushing, water retention in soft tissue, and mild changes in fasting glucose. These observations are relevant to experimental design and endpoint selection, not to clinical safety conclusions.
Any honest overview of CJC-1295 research has to address the side-effect literature, because these observations directly shape how studies are designed and how animal welfare protocols are structured.
The most consistently reported acute responses in early human studies included transient facial flushing, localised injection-site discomfort, and water retention. The Ionescu 2006 study noted that flushing occurred within minutes of administration in a subset of subjects and resolved quickly. From a research design perspective, this means short-term cardiovascular and haematological baselines are worth capturing before compound introduction.
Glucose metabolism is another area that shows up in the CJC-1295 side effects literature. GH is counter-regulatory to insulin, and sustained elevation of the GH/IGF-1 axis in rodent models has been associated with transient changes in fasting glucose and insulin sensitivity. Studies focused on metabolic endpoints should plan glycaemic sampling at multiple timepoints to characterise the curve rather than capture a single snapshot.
Some researchers also note that very high-dose, long-duration GH elevation in animal models correlates with changes in thyroid function markers. This is consistent with known GH-axis biology and is worth including in endpoint panels for studies running beyond 4 weeks.
None of these observations constitute clinical safety conclusions. CJC-1295 is a research compound intended exclusively for laboratory use. Documenting these physiological responses accurately is part of good science, not a warning against the compound's research utility.
Quality Verification: What a Valid CJC-1295 COA Must Include
A valid CJC-1295 Certificate of Analysis should include: peptide identity confirmation, HPLC purity (typically 98% or greater), mass spectrometry molecular weight verification, batch and lot number, manufacturing date, recommended storage conditions, and independent third-party laboratory details.
Quality verification is where research integrity either holds or breaks down. A batch of CJC-1295 that reads 95% purity on a supplier's internal test but contains unidentified impurities at 5% can introduce confounding variables that invalidate months of data.
The minimum documentation standard for any CJC-1295 peptide used in a credible laboratory setting is a batch-specific COA from an independent third-party laboratory. In-house certificates from the manufacturer alone are not sufficient for serious research programs. Third-party verification removes the obvious conflict of interest and provides an external check on analytical methodology.
HPLC purity is the headline number, but mass spectrometry (MS) confirmation is equally important. HPLC tells you what fraction of the sample elutes at the expected retention time. MS tells you whether the molecule at that retention time actually has the correct molecular weight (approximately 3647 Da for CJC-1295 without DAC, approximately 3768 Da for the DAC variant). Both tests together provide a much stronger identity confirmation than either test alone.
For endocrine and metabolic researchers, microbial testing and endotoxin screening are also relevant, particularly for any in vivo work. Lipopolysaccharide contamination at even low concentrations can trigger inflammatory responses that confound GH-axis measurements.
PeptideValidation.com's certified-vendor framework evaluates suppliers against all of these criteria, including transparent sourcing, batch-specific COA availability, third-party analytical results, and documented quality management systems. Researchers can use this framework as a starting checklist when auditing any new peptide supplier.
CJC-1295 Peptide Benefits Observed in Research Models
Research models using CJC-1295 have reported sustained increases in GH and IGF-1 secretion, shifts in body composition markers in rodent studies, and observable changes in protein turnover and lipolytic activity. These are experimental observations, not proven therapeutic benefits.
The phrase 'CJC-1295 peptide benefits' appears frequently in search queries, so it is worth being precise about what the published evidence actually shows and what it does not.
In multiple rodent studies, CJC-1295 administration produced statistically significant increases in serum GH and IGF-1 concentrations compared to controls. In some long-duration rodent models, these hormonal changes were accompanied by measurable shifts in body composition, specifically reductions in fat-pad mass and increases in lean tissue markers. These findings are consistent with the known biology of the GH/IGF-1 axis.
Protein synthesis markers, particularly in skeletal muscle tissue, have been elevated in several animal studies following sustained GH-axis stimulation via CJC-1295. Lipolytic activity in adipose tissue is also a commonly reported endpoint, reflecting GH's well-characterised role in free fatty acid mobilisation.
What the research does not show, at least not in any rigorous clinical trial format, is confirmed therapeutic efficacy in humans. The human studies conducted to date (most notably the Ionescu 2006 Phase II trial) established pharmacokinetic and pharmacodynamic profiles but were not powered to demonstrate clinical outcomes.
For researchers designing studies, this gap between established mechanism and unproven outcomes is actually a rich area for investigation. CJC-1295's well-characterised receptor binding profile makes it a practical research tool for studying GHRH-axis dynamics, even when the clinical endpoint questions remain open. For a deeper look at all aspects of the compound, see our complete CJC-1295 research guide at PeptideValidation.com.
Sourcing and Handling Research-Grade CJC-1295 in 2026
When sourcing CJC-1295 for laboratory research, prioritise suppliers who provide batch-specific third-party COAs, HPLC purity of 98% or greater, and mass spectrometry identity confirmation. Lyophilized powder format, stored at -20 degrees Celsius, provides the most stable long-term storage for the compound.
Sourcing decisions have a direct impact on data quality. The CJC-1295 peptide market includes a wide range of suppliers with highly variable quality standards. Knowing what to look for makes the difference between a reliable research compound and one that introduces unnecessary experimental noise.
The questions researchers ask most often about sourcing are variants of 'CJC-1295 peptide buy' and 'CJC 1295 peptide price.' On price: research-grade CJC-1295 from a verified supplier with full third-party COA documentation will typically cost more than unverified alternatives. That cost difference is almost always justified when you account for the time and resource investment tied to a study that fails due to compound quality.
For storage and handling, lyophilized powder (the form PeptideValidation.com provides in 5 mg vials) is stable at -20 degrees Celsius for extended periods. Reconstituted solutions should be prepared with sterile bacteriostatic water, used within a defined window (typically 30 days when refrigerated at 2 to 8 degrees Celsius), and never subjected to repeated freeze-thaw cycles, which accelerate aggregation and degradation.
Light exposure accelerates photo-oxidation in peptides. Amber vials or aluminium foil wrapping during storage and handling are simple precautions that preserve compound integrity without adding significant procedural burden.
Finally, always request the COA before placing an order, not after. A supplier who cannot or will not provide a batch-specific third-party COA before purchase is a supplier worth avoiding, regardless of price.
Frequently asked questions
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide, not a steroid. Steroids are lipid-derived molecules built on a four-ring cholesterol backbone. CJC-1295 is a 30-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH) with no steroid ring structure. The two compound classes act through entirely different receptors and mechanisms.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of roughly 30 minutes and produces a shorter, more pulsatile GH signal. CJC-1295 with DAC incorporates a Drug Affinity Complex that allows the peptide to bind serum albumin, extending its half-life to approximately 6 to 8 days in preclinical models. Researchers choose between them based on the kinetic window their study design requires.
What CJC-1295 side effects have been observed in research?
Published studies report transient flushing, localised injection-site reactions, water retention, and mild changes in fasting glucose and insulin sensitivity. These are physiological observations from preclinical and early-phase research, not clinical safety determinations. Researchers should incorporate relevant baseline measurements for these endpoints into their study design.
What purity standard should CJC-1295 meet for laboratory research?
Most research-grade peptide protocols require a minimum HPLC purity of 98% or greater, confirmed by a batch-specific COA from an independent third-party laboratory. Mass spectrometry molecular weight verification should accompany HPLC data to confirm compound identity. For in vivo studies, endotoxin and microbial screening results are also recommended.
How should CJC-1295 lyophilized powder be stored?
Lyophilized CJC-1295 powder should be stored at -20 degrees Celsius in a sealed, light-protected container. Once reconstituted with sterile bacteriostatic water, the solution should be kept at 2 to 8 degrees Celsius and used within 30 days. Avoid repeated freeze-thaw cycles and direct light exposure, both of which accelerate peptide degradation.
What does the CJC-1295 research literature show about GH and IGF-1 effects?
Multiple preclinical studies have documented dose-dependent increases in serum GH and IGF-1 following CJC-1295 administration. The Ionescu 2006 Phase II trial in humans showed GH elevations lasting up to 6 days with the DAC variant. Downstream observations in animal models include shifts in body composition markers and changes in protein turnover, consistent with sustained GH-axis activation.
Related in this series
Want to learn more about CJC-1295?
Explore the details